Literature DB >> 29707267

Consolidation of immunotherapy becomes new standard of care in unresectable stage III non-small cell lung cancer.

Myung-Ju Ahn1.   

Abstract

Entities:  

Year:  2018        PMID： 29707267      PMCID： PMC5906269          DOI： 10.21037/jtd.2018.03.55

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  8 in total

1.  Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.

Authors:  Charles Butts; Mark A Socinski; Paul L Mitchell; Nick Thatcher; Libor Havel; Maciej Krzakowski; Sergiusz Nawrocki; Tudor-Eliade Ciuleanu; Lionel Bosquée; José Manuel Trigo; Alexander Spira; Lise Tremblay; Jan Nyman; Rodryg Ramlau; Gun Wickart-Johansson; Peter Ellis; Oleg Gladkov; José Rodrigues Pereira; Wilfried Ernst Erich Eberhardt; Christoph Helwig; Andreas Schröder; Frances A Shepherd
Journal:  Lancet Oncol       Date:  2013-12-09       Impact factor: 41.316

2.  Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.

Authors:  Roy S Herbst; Paul Baas; Dong-Wan Kim; Enriqueta Felip; José L Pérez-Gracia; Ji-Youn Han; Julian Molina; Joo-Hang Kim; Catherine Dubos Arvis; Myung-Ju Ahn; Margarita Majem; Mary J Fidler; Gilberto de Castro; Marcelo Garrido; Gregory M Lubiniecki; Yue Shentu; Ellie Im; Marisa Dolled-Filhart; Edward B Garon
Journal:  Lancet       Date:  2015-12-19       Impact factor: 79.321

3.  Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.

Authors:  Julie Brahmer; Karen L Reckamp; Paul Baas; Lucio Crinò; Wilfried E E Eberhardt; Elena Poddubskaya; Scott Antonia; Adam Pluzanski; Everett E Vokes; Esther Holgado; David Waterhouse; Neal Ready; Justin Gainor; Osvaldo Arén Frontera; Libor Havel; Martin Steins; Marina C Garassino; Joachim G Aerts; Manuel Domine; Luis Paz-Ares; Martin Reck; Christine Baudelet; Christopher T Harbison; Brian Lestini; David R Spigel
Journal:  N Engl J Med       Date:  2015-05-31       Impact factor: 91.245

4.  Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.

Authors:  Jeffrey D Bradley; Rebecca Paulus; Ritsuko Komaki; Gregory Masters; George Blumenschein; Steven Schild; Jeffrey Bogart; Chen Hu; Kenneth Forster; Anthony Magliocco; Vivek Kavadi; Yolanda I Garces; Samir Narayan; Puneeth Iyengar; Cliff Robinson; Raymond B Wynn; Christopher Koprowski; Joanne Meng; Jonathan Beitler; Rakesh Gaur; Walter Curran; Hak Choy
Journal:  Lancet Oncol       Date:  2015-01-16       Impact factor: 41.316

5.  Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04.

Authors:  Jin Seok Ahn; Yong Chan Ahn; Joo-Hang Kim; Chang Geol Lee; Eun Kyung Cho; Kyu Chan Lee; Ming Chen; Dong-Wan Kim; Hoon-Kyo Kim; Young Joo Min; Jin-Hyoung Kang; Jin-Hyuck Choi; Sang-We Kim; Guangying Zhu; Yi-Long Wu; Sung Rok Kim; Kyung Hee Lee; Hong Suk Song; Yoon-La Choi; Jong-Mu Sun; Sin-Ho Jung; Myung-Ju Ahn; Keunchil Park
Journal:  J Clin Oncol       Date:  2015-07-06       Impact factor: 44.544

6.  Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.

Authors:  Scott J Antonia; Augusto Villegas; Davey Daniel; David Vicente; Shuji Murakami; Rina Hui; Takashi Yokoi; Alberto Chiappori; Ki H Lee; Maike de Wit; Byoung C Cho; Maryam Bourhaba; Xavier Quantin; Takaaki Tokito; Tarek Mekhail; David Planchard; Young-Chul Kim; Christos S Karapetis; Sandrine Hiret; Gyula Ostoros; Kaoru Kubota; Jhanelle E Gray; Luis Paz-Ares; Javier de Castro Carpeño; Catherine Wadsworth; Giovanni Melillo; Haiyi Jiang; Yifan Huang; Phillip A Dennis; Mustafa Özgüroğlu
Journal:  N Engl J Med       Date:  2017-09-08       Impact factor: 91.245

7.  Radiotherapy for Non-Small Cell Lung Cancer Induces DNA Damage Response in Both Irradiated and Out-of-field Normal Tissues.

Authors:  Shankar Siva; Pavel Lobachevsky; Michael P MacManus; Tomas Kron; Andreas Möller; Richard J Lobb; Jessica Ventura; Nickala Best; Jai Smith; David Ball; Olga A Martin
Journal:  Clin Cancer Res       Date:  2016-06-03       Impact factor: 12.531

8.  PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Suresh Senan; Anthony Brade; Lu-Hua Wang; Johan Vansteenkiste; Shaker Dakhil; Bonne Biesma; Maite Martinez Aguillo; Joachim Aerts; Ramaswamy Govindan; Belén Rubio-Viqueira; Conrad Lewanski; David Gandara; Hak Choy; Tony Mok; Anwar Hossain; Neill Iscoe; Joseph Treat; Andrew Koustenis; Bélen San Antonio; Nadia Chouaki; Everett Vokes
Journal:  J Clin Oncol       Date:  2016-01-25       Impact factor: 44.544
  8 in total
  2 in total

Review 1.  Immunosuppressive circuits in tumor microenvironment and their influence on cancer treatment efficacy.

Authors:  Alessandra Tuccitto; Eriomina Shahaj; Elisabetta Vergani; Simona Ferro; Veronica Huber; Monica Rodolfo; Chiara Castelli; Licia Rivoltini; Viviana Vallacchi
Journal:  Virchows Arch       Date:  2018-10-29       Impact factor: 4.064

2.  Radiation and immune checkpoint inhibitor-mediated pneumonitis risk stratification in patients with locally advanced non-small cell lung cancer: role of functional lung radiomics?

Authors:  Hannah M T Thomas; Daniel S Hippe; Parisa Forouzannezhad; Balu Krishna Sasidharan; Paul E Kinahan; Robert S Miyaoka; Hubert J Vesselle; Ramesh Rengan; Jing Zeng; Stephen R Bowen
Journal:  Discov Oncol       Date:  2022-09-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.